Last reviewed · How we verify
Placebo+Standard Therapy — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo+Standard Therapy (Placebo+Standard Therapy) — Jiangsu HengRui Medicine Co., Ltd.. This drug is a placebo in combination with standard therapy.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo+Standard Therapy TARGET | Placebo+Standard Therapy | Jiangsu HengRui Medicine Co., Ltd. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo+Standard Therapy CI watch — RSS
- Placebo+Standard Therapy CI watch — Atom
- Placebo+Standard Therapy CI watch — JSON
- Placebo+Standard Therapy alone — RSS
Cite this brief
Drug Landscape (2026). Placebo+Standard Therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-standard-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab